Affimed (NASDAQ:AFMD) Receives $13.50 Consensus Target Price from Brokerages

Affimed (NASDAQ:AFMD) has been assigned a consensus recommendation of “Moderate Buy” from the five analysts that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $13.50.

A number of equities research analysts have recently commented on the stock. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Affimed in a report on Tuesday, December 10th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Affimed in a research note on Tuesday, November 19th. Wells Fargo & Company decreased their price target on Affimed from $20.00 to $15.00 and set an “overweight” rating for the company in a research note on Thursday, December 12th. Finally, Stifel Nicolaus dropped their price objective on Affimed from $5.00 to $4.00 and set a “hold” rating on the stock in a research report on Friday, November 15th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of AFMD. Jane Street Group LLC purchased a new stake in shares of Affimed in the 3rd quarter worth $44,000. Choreo LLC bought a new stake in Affimed during the second quarter valued at about $54,000. FMR LLC increased its position in Affimed by 30.0% in the third quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock worth $59,000 after buying an additional 4,086 shares in the last quarter. Intellectus Partners LLC raised its stake in shares of Affimed by 12.2% in the third quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock worth $317,000 after buying an additional 10,250 shares during the period. Finally, Point72 Asset Management L.P. raised its stake in shares of Affimed by 4.6% in the third quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock worth $1,152,000 after buying an additional 15,108 shares during the period. 30.82% of the stock is owned by hedge funds and other institutional investors.

Affimed Stock Down 6.3 %

Shares of AFMD stock opened at $1.18 on Tuesday. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.93 and a quick ratio of 1.93. Affimed has a one year low of $1.15 and a one year high of $8.95. The company’s 50-day moving average is $2.99 and its 200 day moving average is $4.12.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.